AMD
Astellas announces FDA approval for Izervay for GA treatment
August 7, 2023Medical Communications AMD, Astellas Pharma, FDA, Izervay, Opthalmology, geographic atrophy
Astellas Pharma has announced that the US Food and Drug Administration (FDA) has approved Izervay (avacincaptag pegol intravitreal solution) for …
FDA clears Roche eye drug
February 9, 2015Sales and Marketing AMD, DME, FDA, Lucentis, Retina, Roche, eyes, ranibizumab
The US Food and Drug Administration has shown Roche’s eye-condition drug Lucentis the green light to treat patients with diabetic …
Novartis launches Facebook ‘retina app’
October 15, 2013Medical Communications AMD, Bayer, Lucentis, Novartis, set your sights
Novartis, the world’s biggest eye-care drugmaker, has launched a new Facebook retina app to raise awareness of retinal disease. The …
Sanofi ups stake in Regeneron
February 13, 2013Sales and Marketing AMD, Regeneron, Sanofi, Zaltrap
Sanofi is increasing its stake in Regeneron Pharmaceuticals by buying shares on the open market and from existing shareholders. The …
Novartis eye drug nears approval
January 21, 2013Sales and Marketing AMD, CHMP, Jetria, Novartis
Novartis’ eye drug Jetrea has been given a positive opinion by the CHMP, pushing it to the brink of approval. …
Microneedles could transform delivery of drugs to the eye
July 24, 2012Manufacturing and Production, Research and Development AMD, avastin, microneedles
Researchers in the US have demonstrated for the first time that drugs can be successfully delivered to the eye using …
Stem cell trial aims to cure macular degeneration
June 17, 2011Research and Development AMD, Advanced Cell Technology, Stargardt’s Macular Dystrophy, Stem cells, stem cell
A groundbreaking trial to explore the use of stem cells to treat macular degeneration has been launched. US company Advanced …
Lucentis boosted by diabetic vision study
May 24, 2010Research and Development, Sales and Marketing AMD, DME, Lucentis, Novartis
A phase III trial of Novartis’ ranibizumab has shown it to be superior at promoting vision gain in patients with …
Novartis and charity team up on AMD campaign
February 18, 2009Medical Communications, Sales and Marketing AMD, ophthalmology
Novartis has teamed up with blindness charity the RNIB on a new campaign to promote awareness of age-related macular degeneration …
NICE bends to pressure over Lucentis
December 14, 2007Sales and Marketing AMD, Lucentis, NICE
NICE is set to change its guidance for blindness treatment Lucentis following a barrage of complaints over its failure to …
NICE to re-think blindness drugs decision
August 9, 2007Sales and Marketing AMD, Lucentis, Macugen, NICE
NICE will delay issuing final guidance on two blindness drugs after an unprecedented patient outcry over its decision to block …
NICE set to block blindness drugs
June 15, 2007Sales and Marketing AMD, Lucentis, Macugen, NICE
Most patients in England and Wales will be denied access to drugs for the leading cause of sight loss if …
New blindness treatment moves closer to market
November 28, 2006Sales and Marketing AMD, Lucentis, Novartis
Patients suffering from the leading cause of blindness could soon benefit from a new treatment after it gained preliminary approval …
New Novartis blindness treatment filed in Europe
March 2, 2006Sales and Marketing AMD, Lucentis, Novartis
Lucentis, a new treatment for neovascular age-related macular degeneration or ‘wet AMD’ has been submitted by Novartis to the European …
Latest content
